Comparative Study of the Cellular Pharmacodynamics of Calcineurin Inhibitors between Patients with Chronic Renal Failure Awaiting Renal Transplantation and Cirrhosis Patients Awaiting Liver Transplantation

The in vitro response of peripheral blood mononuclear cells (PBMCs) to the suppressive effects of calcineurin inhibitors is known to correlate with the clinical efficacy of drugs used in renal transplantations. The present study was conducted to examine the differences of PBMC responses to calcineur...

Full description

Bibliographic Details
Main Authors: Yu Kihara, Naoto Matsuno, Abuduxukuer Mijiti, Takeshi Nagao, Hironori Takeuchi, Sakae Unezaki, Toshihiko Hirano Ph.D.
Format: Article
Language:English
Published: SAGE Publishing 2009-05-01
Series:Cell Transplantation
Online Access:https://doi.org/10.1177/096368970901805-620
_version_ 1818415628327845888
author Yu Kihara
Naoto Matsuno
Abuduxukuer Mijiti
Takeshi Nagao
Hironori Takeuchi
Sakae Unezaki
Toshihiko Hirano Ph.D.
author_facet Yu Kihara
Naoto Matsuno
Abuduxukuer Mijiti
Takeshi Nagao
Hironori Takeuchi
Sakae Unezaki
Toshihiko Hirano Ph.D.
author_sort Yu Kihara
collection DOAJ
description The in vitro response of peripheral blood mononuclear cells (PBMCs) to the suppressive effects of calcineurin inhibitors is known to correlate with the clinical efficacy of drugs used in renal transplantations. The present study was conducted to examine the differences of PBMC responses to calcineurin inhibitors between chronic renal failure (CRF) patients awaiting renal transplantation and cirrhosis patients awaiting liver transplantation. The study included 99 CRF patients awaiting renal transplantation and 27 cirrhosis patients awaiting liver transplantation. Twenty milliliters of venous blood was taken 1–7 days before transplantation. The in vitro drug concentrations giving 50% inhibition of PBMC blastogenesis stimulated with concanavalin A (IC 50 s) were calculated. The suppressive effects of tacrolimus against PBMC blastogenesis were more than 10–100 times stronger than those of cyclosporine. The median IC 50 value for cyclosporine against the CRF PBMCs was not significantly different from the median IC 50 value against the cirrhosis PBMCs. In contrast, tacrolimus sensitivity in cirrhosis PBMCs is approximately seven times higher than that in CRF PBMCs. The median IC 50 value for tacrolimus against cirrhosis PBMCs was significantly lower and therefore the effect was stronger in comparison to the CRF PBMCs ( p < 0.001). These data suggest that the PBMCs of cirrhosis patients, in comparison to those of CRF patients, are highly sensitive to the suppressive effect of tacrolimus. However, PBMC sensitivity to cyclosporine was not significantly different between the CRF and cirrhosis patients. These observations raise the possibility that treatment with tacrolimus, rather than cyclosporine, may therefore be a better choice to reduce the risks of allograft rejection in liver transplantation.
first_indexed 2024-12-14T11:38:01Z
format Article
id doaj.art-aadbc66eb54c4dd5a6075b915bfaaf51
institution Directory Open Access Journal
issn 0963-6897
1555-3892
language English
last_indexed 2024-12-14T11:38:01Z
publishDate 2009-05-01
publisher SAGE Publishing
record_format Article
series Cell Transplantation
spelling doaj.art-aadbc66eb54c4dd5a6075b915bfaaf512022-12-21T23:02:57ZengSAGE PublishingCell Transplantation0963-68971555-38922009-05-011810.1177/096368970901805-620Comparative Study of the Cellular Pharmacodynamics of Calcineurin Inhibitors between Patients with Chronic Renal Failure Awaiting Renal Transplantation and Cirrhosis Patients Awaiting Liver TransplantationYu Kihara0Naoto Matsuno1Abuduxukuer Mijiti2Takeshi Nagao3Hironori Takeuchi4Sakae Unezaki5Toshihiko Hirano Ph.D.6Department of 5th Surgery, Hachioji Medical Center, Tokyo Medical University, Tokyo, JapanDepartment of 5th Surgery, Hachioji Medical Center, Tokyo Medical University, Tokyo, JapanDepartment of 5th Surgery, Hachioji Medical Center, Tokyo Medical University, Tokyo, JapanDepartment of 5th Surgery, Hachioji Medical Center, Tokyo Medical University, Tokyo, JapanDepartment of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, JapanDepartment of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, JapanDepartment of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, JapanThe in vitro response of peripheral blood mononuclear cells (PBMCs) to the suppressive effects of calcineurin inhibitors is known to correlate with the clinical efficacy of drugs used in renal transplantations. The present study was conducted to examine the differences of PBMC responses to calcineurin inhibitors between chronic renal failure (CRF) patients awaiting renal transplantation and cirrhosis patients awaiting liver transplantation. The study included 99 CRF patients awaiting renal transplantation and 27 cirrhosis patients awaiting liver transplantation. Twenty milliliters of venous blood was taken 1–7 days before transplantation. The in vitro drug concentrations giving 50% inhibition of PBMC blastogenesis stimulated with concanavalin A (IC 50 s) were calculated. The suppressive effects of tacrolimus against PBMC blastogenesis were more than 10–100 times stronger than those of cyclosporine. The median IC 50 value for cyclosporine against the CRF PBMCs was not significantly different from the median IC 50 value against the cirrhosis PBMCs. In contrast, tacrolimus sensitivity in cirrhosis PBMCs is approximately seven times higher than that in CRF PBMCs. The median IC 50 value for tacrolimus against cirrhosis PBMCs was significantly lower and therefore the effect was stronger in comparison to the CRF PBMCs ( p < 0.001). These data suggest that the PBMCs of cirrhosis patients, in comparison to those of CRF patients, are highly sensitive to the suppressive effect of tacrolimus. However, PBMC sensitivity to cyclosporine was not significantly different between the CRF and cirrhosis patients. These observations raise the possibility that treatment with tacrolimus, rather than cyclosporine, may therefore be a better choice to reduce the risks of allograft rejection in liver transplantation.https://doi.org/10.1177/096368970901805-620
spellingShingle Yu Kihara
Naoto Matsuno
Abuduxukuer Mijiti
Takeshi Nagao
Hironori Takeuchi
Sakae Unezaki
Toshihiko Hirano Ph.D.
Comparative Study of the Cellular Pharmacodynamics of Calcineurin Inhibitors between Patients with Chronic Renal Failure Awaiting Renal Transplantation and Cirrhosis Patients Awaiting Liver Transplantation
Cell Transplantation
title Comparative Study of the Cellular Pharmacodynamics of Calcineurin Inhibitors between Patients with Chronic Renal Failure Awaiting Renal Transplantation and Cirrhosis Patients Awaiting Liver Transplantation
title_full Comparative Study of the Cellular Pharmacodynamics of Calcineurin Inhibitors between Patients with Chronic Renal Failure Awaiting Renal Transplantation and Cirrhosis Patients Awaiting Liver Transplantation
title_fullStr Comparative Study of the Cellular Pharmacodynamics of Calcineurin Inhibitors between Patients with Chronic Renal Failure Awaiting Renal Transplantation and Cirrhosis Patients Awaiting Liver Transplantation
title_full_unstemmed Comparative Study of the Cellular Pharmacodynamics of Calcineurin Inhibitors between Patients with Chronic Renal Failure Awaiting Renal Transplantation and Cirrhosis Patients Awaiting Liver Transplantation
title_short Comparative Study of the Cellular Pharmacodynamics of Calcineurin Inhibitors between Patients with Chronic Renal Failure Awaiting Renal Transplantation and Cirrhosis Patients Awaiting Liver Transplantation
title_sort comparative study of the cellular pharmacodynamics of calcineurin inhibitors between patients with chronic renal failure awaiting renal transplantation and cirrhosis patients awaiting liver transplantation
url https://doi.org/10.1177/096368970901805-620
work_keys_str_mv AT yukihara comparativestudyofthecellularpharmacodynamicsofcalcineurininhibitorsbetweenpatientswithchronicrenalfailureawaitingrenaltransplantationandcirrhosispatientsawaitinglivertransplantation
AT naotomatsuno comparativestudyofthecellularpharmacodynamicsofcalcineurininhibitorsbetweenpatientswithchronicrenalfailureawaitingrenaltransplantationandcirrhosispatientsawaitinglivertransplantation
AT abuduxukuermijiti comparativestudyofthecellularpharmacodynamicsofcalcineurininhibitorsbetweenpatientswithchronicrenalfailureawaitingrenaltransplantationandcirrhosispatientsawaitinglivertransplantation
AT takeshinagao comparativestudyofthecellularpharmacodynamicsofcalcineurininhibitorsbetweenpatientswithchronicrenalfailureawaitingrenaltransplantationandcirrhosispatientsawaitinglivertransplantation
AT hironoritakeuchi comparativestudyofthecellularpharmacodynamicsofcalcineurininhibitorsbetweenpatientswithchronicrenalfailureawaitingrenaltransplantationandcirrhosispatientsawaitinglivertransplantation
AT sakaeunezaki comparativestudyofthecellularpharmacodynamicsofcalcineurininhibitorsbetweenpatientswithchronicrenalfailureawaitingrenaltransplantationandcirrhosispatientsawaitinglivertransplantation
AT toshihikohiranophd comparativestudyofthecellularpharmacodynamicsofcalcineurininhibitorsbetweenpatientswithchronicrenalfailureawaitingrenaltransplantationandcirrhosispatientsawaitinglivertransplantation